Overview
Sweden medical devices and genetic testing firm's Q1 sales rose 5% in local currencies, down 4% in SEK
Q1 net income and EPS were flat yr/yr at SEK 101 mln and SEK 0.74
Gross margin improved to 59.9% from 57.4% in Q1 last yr
Outlook
Vitrolife did not provide specific guidance or outlook for the current or future periods in its press release
Result Drivers
REGIONAL PERFORMANCE - Sales growth in local currencies was driven by 11% increase in Americas and 7% in APAC, while EMEA declined 1%
PRODUCT GROUPS - Consumables and Technologies sales rose 9% and 11% respectively in local currencies, while Genetics fell 1%
GROSS MARGIN IMPROVEMENT - Gross margin increased to 59.9% from 57.4% in Q1 last year
Company press release: ID:nWkr6RWbSK
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 807 mln
Q1 EPS
SEK 0.74
Q1 Net Income
SEK 101 mln
Q1 EBITDA
SEK 251 mln
Q1 EBITDA Margin
31.10%
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Vitrolife AB is SEK150.00, about 40.4% above its April 22 closing price of SEK106.80
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 33 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)